In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis

Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this dr...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Sun, Jian [verfasserIn] Xiao, Xia Huang, Rui-Juan Yang, Tao Chen, Yi Fang, Xi Huang, Ting Zhou, Yu-Feng Liu, Ya-Hong

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2015

Schlagwörter:	Marbofloxacin PK/PD CO Monte Carlo simulation

Anmerkung:	© Sun et al. 2015

Übergeordnetes Werk:	Enthalten in: BMC veterinary research - London : BioMed Central, 2005, 11(2015), 1 vom: 01. Dez.
Übergeordnetes Werk:	volume:11 ; year:2015 ; number:1 ; day:01 ; month:12

Links:	Volltext

DOI / URN:	10.1186/s12917-015-0604-5

Katalog-ID:	SPR028384431

Internformat


LEADER	01000caa a22002652 4500
001	SPR028384431
003	DE-627
005	20230519071025.0
007	cr uuu---uuuuu
008	201007s2015 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1186/s12917-015-0604-5 \|2 doi
035			\|a (DE-627)SPR028384431
035			\|a (SPR)s12917-015-0604-5-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	1		\|a Sun, Jian \|e verfasserin \|4 aut
245	1	0	\|a In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis
264		1	\|c 2015
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Sun et al. 2015
520			\|a Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination.
650		4	\|a Marbofloxacin \|7 (dpeaa)DE-He213
650		4	\|a PK/PD \|7 (dpeaa)DE-He213
650		4	\|a CO \|7 (dpeaa)DE-He213
650		4	\|a Monte Carlo simulation \|7 (dpeaa)DE-He213
700	1		\|a Xiao, Xia \|4 aut
700	1		\|a Huang, Rui-Juan \|4 aut
700	1		\|a Yang, Tao \|4 aut
700	1		\|a Chen, Yi \|4 aut
700	1		\|a Fang, Xi \|4 aut
700	1		\|a Huang, Ting \|4 aut
700	1		\|a Zhou, Yu-Feng \|4 aut
700	1		\|a Liu, Ya-Hong \|4 aut
773	0	8	\|i Enthalten in \|t BMC veterinary research \|d London : BioMed Central, 2005 \|g 11(2015), 1 vom: 01. Dez. \|w (DE-627)489256538 \|w (DE-600)2191675-5 \|x 1746-6148 \|7 nnns
773	1	8	\|g volume:11 \|g year:2015 \|g number:1 \|g day:01 \|g month:12
856	4	0	\|u https://dx.doi.org/10.1186/s12917-015-0604-5 \|z kostenfrei \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 11 \|j 2015 \|e 1 \|b 01 \|c 12

Indexfelder

author_variant	j s js x x xx r j h rjh t y ty y c yc x f xf t h th y f z yfz y h l yhl
matchkey_str	article:17466148:2015----::nirdnmchraoieipaacdnmckdtdadopomrolxc
hierarchy_sort_str	2015
publishDate	2015
allfields	10.1186/s12917-015-0604-5 doi (DE-627)SPR028384431 (SPR)s12917-015-0604-5-e DE-627 ger DE-627 rakwb eng Sun, Jian verfasserin aut In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Sun et al. 2015 Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination. Marbofloxacin (dpeaa)DE-He213 PK/PD (dpeaa)DE-He213 CO (dpeaa)DE-He213 Monte Carlo simulation (dpeaa)DE-He213 Xiao, Xia aut Huang, Rui-Juan aut Yang, Tao aut Chen, Yi aut Fang, Xi aut Huang, Ting aut Zhou, Yu-Feng aut Liu, Ya-Hong aut Enthalten in BMC veterinary research London : BioMed Central, 2005 11(2015), 1 vom: 01. Dez. (DE-627)489256538 (DE-600)2191675-5 1746-6148 nnns volume:11 year:2015 number:1 day:01 month:12 https://dx.doi.org/10.1186/s12917-015-0604-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2015 1 01 12
spelling	10.1186/s12917-015-0604-5 doi (DE-627)SPR028384431 (SPR)s12917-015-0604-5-e DE-627 ger DE-627 rakwb eng Sun, Jian verfasserin aut In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Sun et al. 2015 Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination. Marbofloxacin (dpeaa)DE-He213 PK/PD (dpeaa)DE-He213 CO (dpeaa)DE-He213 Monte Carlo simulation (dpeaa)DE-He213 Xiao, Xia aut Huang, Rui-Juan aut Yang, Tao aut Chen, Yi aut Fang, Xi aut Huang, Ting aut Zhou, Yu-Feng aut Liu, Ya-Hong aut Enthalten in BMC veterinary research London : BioMed Central, 2005 11(2015), 1 vom: 01. Dez. (DE-627)489256538 (DE-600)2191675-5 1746-6148 nnns volume:11 year:2015 number:1 day:01 month:12 https://dx.doi.org/10.1186/s12917-015-0604-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2015 1 01 12
allfields_unstemmed	10.1186/s12917-015-0604-5 doi (DE-627)SPR028384431 (SPR)s12917-015-0604-5-e DE-627 ger DE-627 rakwb eng Sun, Jian verfasserin aut In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Sun et al. 2015 Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination. Marbofloxacin (dpeaa)DE-He213 PK/PD (dpeaa)DE-He213 CO (dpeaa)DE-He213 Monte Carlo simulation (dpeaa)DE-He213 Xiao, Xia aut Huang, Rui-Juan aut Yang, Tao aut Chen, Yi aut Fang, Xi aut Huang, Ting aut Zhou, Yu-Feng aut Liu, Ya-Hong aut Enthalten in BMC veterinary research London : BioMed Central, 2005 11(2015), 1 vom: 01. Dez. (DE-627)489256538 (DE-600)2191675-5 1746-6148 nnns volume:11 year:2015 number:1 day:01 month:12 https://dx.doi.org/10.1186/s12917-015-0604-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2015 1 01 12
allfieldsGer	10.1186/s12917-015-0604-5 doi (DE-627)SPR028384431 (SPR)s12917-015-0604-5-e DE-627 ger DE-627 rakwb eng Sun, Jian verfasserin aut In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Sun et al. 2015 Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination. Marbofloxacin (dpeaa)DE-He213 PK/PD (dpeaa)DE-He213 CO (dpeaa)DE-He213 Monte Carlo simulation (dpeaa)DE-He213 Xiao, Xia aut Huang, Rui-Juan aut Yang, Tao aut Chen, Yi aut Fang, Xi aut Huang, Ting aut Zhou, Yu-Feng aut Liu, Ya-Hong aut Enthalten in BMC veterinary research London : BioMed Central, 2005 11(2015), 1 vom: 01. Dez. (DE-627)489256538 (DE-600)2191675-5 1746-6148 nnns volume:11 year:2015 number:1 day:01 month:12 https://dx.doi.org/10.1186/s12917-015-0604-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2015 1 01 12
allfieldsSound	10.1186/s12917-015-0604-5 doi (DE-627)SPR028384431 (SPR)s12917-015-0604-5-e DE-627 ger DE-627 rakwb eng Sun, Jian verfasserin aut In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Sun et al. 2015 Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination. Marbofloxacin (dpeaa)DE-He213 PK/PD (dpeaa)DE-He213 CO (dpeaa)DE-He213 Monte Carlo simulation (dpeaa)DE-He213 Xiao, Xia aut Huang, Rui-Juan aut Yang, Tao aut Chen, Yi aut Fang, Xi aut Huang, Ting aut Zhou, Yu-Feng aut Liu, Ya-Hong aut Enthalten in BMC veterinary research London : BioMed Central, 2005 11(2015), 1 vom: 01. Dez. (DE-627)489256538 (DE-600)2191675-5 1746-6148 nnns volume:11 year:2015 number:1 day:01 month:12 https://dx.doi.org/10.1186/s12917-015-0604-5 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2015 1 01 12
language	English
source	Enthalten in BMC veterinary research 11(2015), 1 vom: 01. Dez. volume:11 year:2015 number:1 day:01 month:12
sourceStr	Enthalten in BMC veterinary research 11(2015), 1 vom: 01. Dez. volume:11 year:2015 number:1 day:01 month:12
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Marbofloxacin PK/PD CO Monte Carlo simulation
isfreeaccess_bool	true
container_title	BMC veterinary research
authorswithroles_txt_mv	Sun, Jian @@aut@@ Xiao, Xia @@aut@@ Huang, Rui-Juan @@aut@@ Yang, Tao @@aut@@ Chen, Yi @@aut@@ Fang, Xi @@aut@@ Huang, Ting @@aut@@ Zhou, Yu-Feng @@aut@@ Liu, Ya-Hong @@aut@@
publishDateDaySort_date	2015-12-01T00:00:00Z
hierarchy_top_id	489256538
id	SPR028384431
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR028384431</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519071025.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2015 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s12917-015-0604-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR028384431</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12917-015-0604-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sun, Jian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Sun et al. 2015</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Marbofloxacin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">PK/PD</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CO</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Monte Carlo simulation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xiao, Xia</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huang, Rui-Juan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Tao</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Yi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fang, Xi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huang, Ting</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhou, Yu-Feng</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Ya-Hong</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BMC veterinary research</subfield><subfield code="d">London : BioMed Central, 2005</subfield><subfield code="g">11(2015), 1 vom: 01. Dez.</subfield><subfield code="w">(DE-627)489256538</subfield><subfield code="w">(DE-600)2191675-5</subfield><subfield code="x">1746-6148</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">day:01</subfield><subfield code="g">month:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s12917-015-0604-5</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="b">01</subfield><subfield code="c">12</subfield></datafield></record></collection>
author	Sun, Jian
spellingShingle	Sun, Jian misc Marbofloxacin misc PK/PD misc CO misc Monte Carlo simulation In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis
authorStr	Sun, Jian
ppnlink_with_tag_str_mv	@@773@@(DE-627)489256538
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1746-6148
topic_title	In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis Marbofloxacin (dpeaa)DE-He213 PK/PD (dpeaa)DE-He213 CO (dpeaa)DE-He213 Monte Carlo simulation (dpeaa)DE-He213
topic	misc Marbofloxacin misc PK/PD misc CO misc Monte Carlo simulation
topic_unstemmed	misc Marbofloxacin misc PK/PD misc CO misc Monte Carlo simulation
topic_browse	misc Marbofloxacin misc PK/PD misc CO misc Monte Carlo simulation
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	BMC veterinary research
hierarchy_parent_id	489256538
hierarchy_top_title	BMC veterinary research
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)489256538 (DE-600)2191675-5
title	In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis
ctrlnum	(DE-627)SPR028384431 (SPR)s12917-015-0604-5-e
title_full	In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis
author_sort	Sun, Jian
journal	BMC veterinary research
journalStr	BMC veterinary research
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2015
contenttype_str_mv	txt
author_browse	Sun, Jian Xiao, Xia Huang, Rui-Juan Yang, Tao Chen, Yi Fang, Xi Huang, Ting Zhou, Yu-Feng Liu, Ya-Hong
container_volume	11
format_se	Elektronische Aufsätze
author-letter	Sun, Jian
doi_str_mv	10.1186/s12917-015-0604-5
title_sort	in vitro dynamic pharmacokinetic/pharamcodynamic (pk/pd) study and $ co_{pd} $ of marbofloxacin against haemophilus parasuis
title_auth	In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis
abstract	Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination. © Sun et al. 2015
abstractGer	Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination. © Sun et al. 2015
abstract_unstemmed	Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination. © Sun et al. 2015
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis
url	https://dx.doi.org/10.1186/s12917-015-0604-5
remote_bool	true
author2	Xiao, Xia Huang, Rui-Juan Yang, Tao Chen, Yi Fang, Xi Huang, Ting Zhou, Yu-Feng Liu, Ya-Hong
author2Str	Xiao, Xia Huang, Rui-Juan Yang, Tao Chen, Yi Fang, Xi Huang, Ting Zhou, Yu-Feng Liu, Ya-Hong
ppnlink	489256538
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1186/s12917-015-0604-5
up_date	2024-07-03T19:08:57.243Z
_version_	1803586096066461696
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR028384431</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519071025.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2015 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s12917-015-0604-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR028384431</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12917-015-0604-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sun, Jian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Sun et al. 2015</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff ($ CO_{PD} $) of this drug against H. parasuis. Results MICs of marbofloxacin against 198 H. parasuis isolates were determined. The $ MIC_{50} $ and $ MIC_{90} $ were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers $ C_{max} $/MIC, $ C_{max} $/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and $ AUC_{24h} $/MIC, $ AUC_{24h} $/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the $ R^{2} $ of 0.9928 and 0.9911, respectively. The target values of 3-$ log_{10} $-unit and 4-$ log_{10} $-unit reduction for $ AUC_{24h} $/MPC were 33 and 42, while the same efficacy for $ AUC_{24h} $/MIC were 88 and 110. The $ CO_{PD} $ deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). Conclusions The PK/PD surrogate markers $ AUC_{24h} $/MIC, $ C_{max} $/MIC and $ AUC_{24h} $/MPC, $ C_{max} $/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first $ CO_{PD} $ provide fundamental data for marbofloxacin breakpoint determination.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Marbofloxacin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">PK/PD</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CO</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Monte Carlo simulation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xiao, Xia</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huang, Rui-Juan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Tao</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Yi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fang, Xi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huang, Ting</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhou, Yu-Feng</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Ya-Hong</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BMC veterinary research</subfield><subfield code="d">London : BioMed Central, 2005</subfield><subfield code="g">11(2015), 1 vom: 01. Dez.</subfield><subfield code="w">(DE-627)489256538</subfield><subfield code="w">(DE-600)2191675-5</subfield><subfield code="x">1746-6148</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">day:01</subfield><subfield code="g">month:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s12917-015-0604-5</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="b">01</subfield><subfield code="c">12</subfield></datafield></record></collection>
score	7.3992815

Nicht das Richtige dabei?

Schreiben Sie uns!

In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and $ CO_{PD} $ of Marbofloxacin against Haemophilus parasuis

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?